TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04482725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 3
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Propylene glycol 18.5 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 3
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Propylene glycol 18.5 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 3
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Propylene glycol 18.5 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 3
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Propylene glycol 18.5 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 3
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Propylene glycol 18.5 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 3
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Propylene glycol 18.5 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 3
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Propylene glycol 18.5 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 3
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Propylene glycol 18.5 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 3
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Propylene glycol 18.5 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 4
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Glycerol 22.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 4
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Glycerol 22.0 mg/mL
Study: NCT05808114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU
Description: Individually tailored and delivered specialized child psychiatric care
Study: NCT02116946

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP)
Description: Injection of Leukocyte-rich or Leukocyte-poor Platelet Rich Plasma prepared by the Angel cPRP System along with a 12 week exercise program for treatment of patients with patellar tendinopathy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP)
Description: Injection of Leukocyte-rich or Leukocyte-poor Platelet Rich Plasma prepared by the Angel cPRP System along with a 12 week exercise program for treatment of patients with patellar tendinopathy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline + exercise
Description: Peritendinous saline injection plus 12 week exercise program.
Study: NCT04482725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 5
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Mannitol 44.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 5
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Mannitol 44.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 5
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Mannitol 44.0 mg/mL
Study: NCT03021070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditional cash transfer
Description: For each honoured and verified health visit that is made on time following enrollment, a woman receives a cash transfer. The value reduces by one quarter for each week of delayed visit, and no reward is offered for any visit made 3 weeks after the appointment date. Transportation cost by a local taxi to the health facility, and is a value that has been approved by the research ethics committee for many studies in the region as reasonable compensation for research participants.
Study: NCT02151110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4920 3 mg
Description: Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4920 10 mg
Description: Participants received single IV dose of MEDI4920 10 mg infused on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4920 30 mg
Description: Participants received single IV dose of MEDI4920 30 mg infused on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4920 100 mg
Description: Participants received single IV dose of MEDI4920 100 mg infused on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4920 300 mg
Description: Participants received single IV dose of MEDI4920 300 mg infused on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4920 1000 mg
Description: Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4920 3000 mg
Description: Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
Study: NCT04482725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 6
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Sucrose 82.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 6
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Sucrose 82.0 mg/mL
Study: NCT02151110

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.
Study: NCT00850590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001
Description: Four single doses of NRL001 or placebo. NRL001 is administered at lower (5, 7.5 and 10 mg) or higher (10, 12.5 and 15 mg) doses in a slow release rectal suppository weighing either 1 g or 2 g.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001
Description: Four single doses of NRL001 or placebo. NRL001 is administered at lower (5, 7.5 and 10 mg) or higher (10, 12.5 and 15 mg) doses in a slow release rectal suppository weighing either 1 g or 2 g.
Study: NCT02398760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Control Exercises
Description: Subjects performed 8 weeks of motor control exercises intervention, 2 weekly 1 hour per session, instructed by trained physiotherapists to apply this program following a protocol developed in programs previously reported (Costa et al. 2009; Hodges et al. 2009). The first stage aims to improve the activity of muscles that have poor control and reduce overactivity of superficial muscles, previously assessed, through drawing in maneuver with feedback real-time ultrasound and via palpation. The second stage of the treatment involved more functional exercises, first using static and then dynamic tasks.
Study: NCT04719286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MinSafeStart app
Description: The intervention is the opportunity of using the MinSafeStart app. Women can register their NVP severity in the app by answering a few questions daily. Based on this, they will get tailored advice on NVP, and get alert when they should see a doctor.
Study: NCT03217812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade
Description: Participants will receive velcade 1.3 mg/m\^2, SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9 of Treatment Arm A and B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Participants will receive velcade 1.3 mg/m\^2, SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9 of Treatment Arm A and B.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Participants will receive melphalan 9 mg/m\^2 (if serum creatine is \>2 mg/dL at baseline, participants must be administrated 4.5 mg/m\^2 of melphalan, instead of 9 mg/m\^2), orally, once daily on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Participants will receive melphalan 9 mg/m\^2 (if serum creatine is \>2 mg/dL at baseline, participants must be administrated 4.5 mg/m\^2 of melphalan, instead of 9 mg/m\^2), orally, once daily on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
Study: NCT04482725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 6
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Sucrose 82.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 6
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Sucrose 82.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 6
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Sucrose 82.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 6
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Sucrose 82.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 6
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Sucrose 82.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 6
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Sucrose 82.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 6
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Sucrose 82.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 6
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Sucrose 82.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 6
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Sucrose 82.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 6
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Sucrose 82.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 7
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: a,a-Trehalose, dihydrate 90.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 7
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: a,a-Trehalose, dihydrate 90.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 7
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: a,a-Trehalose, dihydrate 90.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 7
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: a,a-Trehalose, dihydrate 90.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 7
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: a,a-Trehalose, dihydrate 90.0 mg/mL
Study: NCT03217812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Participants will receive prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
Study: NCT03217812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive daratumumab 16 mg/kg as IV infusion or daratumumab SC, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or the end of study in Treatment Arm B.
Study: NCT02721485

Intervention type: OTHER
Group type: OTHER
Intervention: Ringer's Lactate
Description: After a 1 week run in half of participating hospitals will be crossed over to using Ringer's Lactate as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the second 90-day test period.

Intervention type: OTHER
Group type: OTHER
Intervention: Normal Saline
Description: After a 1 week run in half of participating hospitals will be crossed over to using Normal Saline as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the final 90-day test period.
Study: NCT00827333

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Family Caregiver Palliative Care Intervention at weeks 7, 8, 10, and 12 post study enrollment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: end-of-life treatment/management
Description: Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial assessment and care
Description: Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
Study: NCT04482725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 9
Description: Buffering agent: Tris 2.4 mg/mL Isotonic agent: Propylene glycol 19 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 9
Description: Buffering agent: Tris 2.4 mg/mL Isotonic agent: Propylene glycol 19 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 9
Description: Buffering agent: Tris 2.4 mg/mL Isotonic agent: Propylene glycol 19 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 9
Description: Buffering agent: Tris 2.4 mg/mL Isotonic agent: Propylene glycol 19 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 9
Description: Buffering agent: Tris 2.4 mg/mL Isotonic agent: Propylene glycol 19 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 9
Description: Buffering agent: Tris 2.4 mg/mL Isotonic agent: Propylene glycol 19 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Glutamic acid 0.74 mg/mL Isotonic agent: Glycerol 24.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Glutamic acid 0.74 mg/mL Isotonic agent: Glycerol 24.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Glutamic acid 0.74 mg/mL Isotonic agent: Glycerol 24.0 mg/mL
Study: NCT01918787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive TMS
Description: rTMS (intermittent theta burst stimulation 1200)over posterior superior temporal sulcus,dorsolateral prefrontal cortex and inion as Sham control
Study: NCT04260919

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Study: NCT05485259

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DL-alpha lipoic acid
Description: Treatment group recieves 600 mg of DL-alpha lipoic acid daily, per os, for 3 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo (rice starch)
Description: Placebo group recieves 600 mg (2x300 mg) of placebo (rice starch) daily, per os, for 3 months
Study: NCT03216083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Injectable Solution
Description: 1g IV tranexamic acid mixed in normal saline (67mL)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 67mL IV normal saline
Study: NCT00854555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Locomotor training with robot
Description: 60 days locomotor training during 6 months period in out-patient setting. Minimum 60 min training up to 3 times per week. Control group receives conventional training/treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Locomotor training with manual assistance
Description: 60 days training during 6 months period on in-patient setting. Training 2 times per day total 120 minutes. Control group receives conventional training/treatment.
Study: NCT02746848

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amniotic Membrane Extract Eye Drop
Description: Amniotic Membrane Extract use as eye drop for patients with corneal injury.
Study: NCT02293096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol succinate

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genotyping
Description: CYP2D6 only clinically pertinent pathway of metoprolol metabolism and polymorphisms have been associated with altered levels of metoprolol. ADRB1 is the drug target and polymorphism in this receptor has been associated with variable drug response. Genotyping will occur after the treatment phase is complete. Thus the investigator, the subject, and the outcomes investigator will be blind to the intervention.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CYP2D6 Phenotyping
Description: Phenotype can be discordant from what is predicted by genotype due to variability in absorption, hepatic blood flow, drug interaction and drug elimination. These factors can be accounted for by utilizing a phenotyping assay that determines area under the curve of the probe since the probe is affected by the same variables dictating metabolism phenotype of the therapeutic drug. Investigators will be blind to the patient blood pressure outcome for this intervention.
Study: NCT04482725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Glutamic acid 0.74 mg/mL Isotonic agent: Glycerol 24.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Glutamic acid 0.74 mg/mL Isotonic agent: Glycerol 24.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Glutamic acid 0.74 mg/mL Isotonic agent: Glycerol 24.0 mg/mL
Study: NCT01852695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Integrated Care
Description: Parents are integrated into the care of their infants in the NICU. Parents consent to spending up to eight hours a day with their infant, attend special education sessions, participate in daily medical rounds, and do basic infant charting. This will enable parents to provide care for infants with nursing supervision in the areas of feeding, bathing, dressing and holding skin to skin.
Study: NCT01750944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ankle first
Description: 1. Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right ankles (BPA-LR).~2. A 15 minute walking test (WT) is performed.~3. BBP-LR and BPA-LR are re-measured.~4. 2 hours of rest.~5. BBP-LR and the blood pressure at the left and right big toes (BPT-LR) are measured.~6. WT is reperformed.~7. BBP-LR and BPT-LR are re-measured.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Toe first
Description: 1. Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right big toes (BPT-LR).~2. A 15 minute walking test (WT) is performed.~3. BBP-LR and BPT-LR are re-measured.~4. 2 hours of rest.~5. BBP-LR and the blood pressure at the left and right ankles (BPA-LR) are measured.~6. WT is reperformed.~7. BBP-LR and BPA-LR are re-measured.
Study: NCT00827333

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
Study: NCT04482725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Glutamic acid 0.74 mg/mL Isotonic agent: Glycerol 24.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Glutamic acid 0.74 mg/mL Isotonic agent: Glycerol 24.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Glutamic acid 0.74 mg/mL Isotonic agent: Glycerol 24.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Sodium Acetate, trihydrate 0.68 mg/mL Isotonic agent: Glycerol 24.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Sodium Acetate, trihydrate 0.68 mg/mL Isotonic agent: Glycerol 24.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Sodium Acetate, trihydrate 0.68 mg/mL Isotonic agent: Glycerol 24.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Sodium Acetate, trihydrate 0.68 mg/mL Isotonic agent: Glycerol 24.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Sodium Acetate, trihydrate 0.68 mg/mL Isotonic agent: Glycerol 24.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 10
Description: Buffering agent: Sodium Acetate, trihydrate 0.68 mg/mL Isotonic agent: Glycerol 24.0 mg/mL
Study: NCT01995812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hula and heart health education
Study: NCT00742807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of alfentanil hydrochloride
Description: Administration of low dose alfentanil hydrochloride before paracervical block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal dose of alfentanil hydrochloride
Description: Normal dose of alfentanil hydrochloride is administered after paracervical block
Study: NCT00185354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-5016, SH P00331F
Description: Drug amount per patch: 0.9 mg EE2 + 1.9 mg gestodene (GSD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SH P00331N
Description: Drug amount per patch: 0.6 mg EE2 + 6 mg NGM
Study: NCT00965146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scorpio® CR Total Knee System
Description: All subjects will be implanted with a femoral component, a tibial insert, a tibial tray and a resurfaced patella.